Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00564018 · ClinicalTrials.gov registry record · NA

Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH

A NA study, sponsored by University of Texas Southwestern Medical Center.

Terminated
Registry status
NA
Development phase
33
Enrollment target

NCT00564018 is a NA study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 33 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00564018, a NA study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.

TERMINATED
Registry status
NA
Development phase
33 participants
Enrollment target

Study Summary

To determine whether using a long-acting insulin analog at the time of diagnosis, instead of intermediate-acting insulin, affects the rate of loss of the body's ability to make insulin in children with newly diagnosed type 1 diabetes.

Interventions

  • DRUG Glargine
  • DRUG Insulin detemir
  • DRUG NPH

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2006-09
Est. Completion 2011-04
Phase NA

What the Registry Record Tells You About NCT00564018

The ClinicalTrials.gov registry entry for NCT00564018 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Glargine is the first listed.

NCT00564018 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00564018 about?

NCT00564018 is a clinical study titled "Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH". To determine whether using a long-acting insulin analog at the time of diagnosis, instead of intermediate-acting insulin, affects the rate of loss of the body's ability to make insulin in children with newly diagnosed type 1 diabetes.

What is the current status of trial NCT00564018?

This trial is currently terminated. It is a NA study. The enrollment target is 33 participants. The study started on 2006-09. Estimated completion is 2011-04.

What interventions are being tested in trial NCT00564018?

The interventions under investigation include: Glargine (DRUG), Insulin detemir (DRUG), NPH (DRUG).

Who is sponsoring clinical trial NCT00564018?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.